PURPOSE: Thy-1 is a marker of retinal ganglion cell (RGC) differentiation. Optic nerve injury triggers reduction of Thy-1 promoter activation followed by retinal ganglion cell (RGC) death. This study determined whether MS-275, an inhibitor of the histone deacetylases 1 and 3, can inhibit these changes. METHODS: Mice expressing cyan fluorescent protein (CFP) under control of the Thy-1 promoter received MS-275 (subcutaneous) or vehicle three times per week starting 1 week before optic nerve crush and continuing for 6 weeks. The same retinal area was imaged using the blue-light confocal scanning laser ophthalmoscope before and after optic nerve crush every week, and fluorescent spots were counted manually. The eyes were then processed for histopathologic analysis. RESULTS: The mean proportions of fluorescent retinal neurons remaining in the vehicle group following optic nerve crush were 36 ± 8, 18 ± 6, 13 ± 10, 12 ± 4, 13 ± 5, and 13 ± 5% at weeks 1 through 6, respectively (n = 6). In contrast, the mean proportions of fluorescent retinal neurons remaining in the group treated with MS-275 were 59 ± 19, 39 ± 11, 34 ± 12, 33 ± 15, 32 ± 13, and 27 ± 15% at weeks 1 through 6, respectively (n = 7, P < 0.05 at weeks 1 through 5). Rate analysis showed that MS-275 slowed the rate of loss during the first 2 weeks by 23% (P < 0.05) and subsequently was similar. Histopathologic analysis revealed 27 ± 13% greater ganglion cell layer (GCL) neurons in the eyes from mice that received MS-275 treatment (P < 0.02). CONCLUSIONS: These results indicate that treatment with MS-275 protects against the loss of RGC differentiation and promotes RGC survival following optic nerve injury.
PURPOSE:Thy-1 is a marker of retinal ganglion cell (RGC) differentiation. Optic nerve injury triggers reduction of Thy-1 promoter activation followed by retinal ganglion cell (RGC) death. This study determined whether MS-275, an inhibitor of the histone deacetylases 1 and 3, can inhibit these changes. METHODS:Mice expressing cyan fluorescent protein (CFP) under control of the Thy-1 promoter received MS-275 (subcutaneous) or vehicle three times per week starting 1 week before optic nerve crush and continuing for 6 weeks. The same retinal area was imaged using the blue-light confocal scanning laser ophthalmoscope before and after optic nerve crush every week, and fluorescent spots were counted manually. The eyes were then processed for histopathologic analysis. RESULTS: The mean proportions of fluorescent retinal neurons remaining in the vehicle group following optic nerve crush were 36 ± 8, 18 ± 6, 13 ± 10, 12 ± 4, 13 ± 5, and 13 ± 5% at weeks 1 through 6, respectively (n = 6). In contrast, the mean proportions of fluorescent retinal neurons remaining in the group treated with MS-275 were 59 ± 19, 39 ± 11, 34 ± 12, 33 ± 15, 32 ± 13, and 27 ± 15% at weeks 1 through 6, respectively (n = 7, P < 0.05 at weeks 1 through 5). Rate analysis showed that MS-275 slowed the rate of loss during the first 2 weeks by 23% (P < 0.05) and subsequently was similar. Histopathologic analysis revealed 27 ± 13% greater ganglion cell layer (GCL) neurons in the eyes from mice that received MS-275 treatment (P < 0.02). CONCLUSIONS: These results indicate that treatment with MS-275 protects against the loss of RGC differentiation and promotes RGC survival following optic nerve injury.
Authors: M V Simonini; L M Camargo; E Dong; E Maloku; M Veldic; E Costa; A Guidotti Journal: Proc Natl Acad Sci U S A Date: 2006-01-23 Impact factor: 11.205
Authors: Florian A Siebzehnrubl; Rolf Buslei; Ilker Y Eyupoglu; Sebastian Seufert; Eric Hahnen; Ingmar Blumcke Journal: Exp Brain Res Date: 2007-01-10 Impact factor: 1.972
Authors: G Feng; R H Mellor; M Bernstein; C Keller-Peck; Q T Nguyen; M Wallace; J M Nerbonne; J W Lichtman; J R Sanes Journal: Neuron Date: 2000-10 Impact factor: 17.173
Authors: Fumihiko Mabuchi; Makoto Aihara; Mason R Mackey; James D Lindsey; Robert N Weinreb Journal: Invest Ophthalmol Vis Sci Date: 2003-10 Impact factor: 4.799
Authors: Christopher K S Leung; James D Lindsey; Jonathan G Crowston; Won-Kyu Ju; Qwan Liu; Dirk-Uwe Bartsch; Robert N Weinreb Journal: J Neurosci Methods Date: 2007-11-07 Impact factor: 2.390
Authors: Oday Alsarraf; Jie Fan; Mohammad Dahrouj; C James Chou; Phillip W Yates; Craig E Crosson Journal: Invest Ophthalmol Vis Sci Date: 2014-10-30 Impact factor: 4.799
Authors: Yuqin Yin; Silmara De Lima; Hui-Ya Gilbert; Nicholas J Hanovice; Sheri L Peterson; Rheanna M Sand; Elena G Sergeeva; Kimberly A Wong; Lili Xie; Larry I Benowitz Journal: Restor Neurol Neurosci Date: 2019 Impact factor: 2.406
Authors: Cassandra L Schlamp; Angela D Montgomery; Caitlin E Mac Nair; Claudia Schuart; Daniel J Willmer; Robert W Nickells Journal: Mol Vis Date: 2013-06-27 Impact factor: 2.367
Authors: Yi Dai; James D Lindsey; Karen X Duong-Polk; Panida Chindasub; Christopher Kai-Shun Leung; Robert N Weinreb Journal: BMC Ophthalmol Date: 2013-06-27 Impact factor: 2.209
Authors: James D Lindsey; Karen X Duong-Polk; Yi Dai; Duy H Nguyen; Christopher K Leung; Robert N Weinreb Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240